New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 8, 2012
09:37 EDTZGNXZogenix announces FDA Advisory Committee to review Zohydro ER NDA on Dec. 7
Zogenix announced that the U.S. FDA Anesthetic and Analgesic Drug Products Advisory Committee, or AADPAC, will review the company's New Drug Application, or NDA, for Zohydro ER -- hydrocodone bitartrate extended-release capsules -- on Dec. 7, 2012. Zohydro ER is Zogenix's lead investigational product candidate for the management of moderate-to-severe chronic pain when a continuous, around-the-clock opioid analgesic is needed for an extended period of time. Details of the meeting agenda will be available in the Federal Register. The Prescription Drug User Fee Act, or PDUFA, date for completion of the review by the FDA is March 1, 2013. If approved, Zohydro ER will be classified as a Drug Enforcement Agency, or DEA, Schedule II drug, subject to stricter prescribing and dispensing rules compared to the currently prescribed hydrocodone products.
News For ZGNX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 25, 2015
13:43 EDTZGNXZogenix epilepsy meeting abstracts encouraging, says Leerink
Leerink analyst Paul Matteis noted that three abstracts to be presented by Zogenix at the American Epilepsy Society were made available this morning, stating that new data on seven additional patients treated with fenfluramine add support to the clinical potential of the drug as a Dravet Syndrome treatment. Matteis reiterates an Outperform rating on Zogenix.

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use